Published in J Hepatol on March 01, 1993
KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol (2012) 2.10
Transfusion-transmitted infections. J Transl Med (2007) 1.39
KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol (2016) 1.07
Occult hepatitis B infection and its possible impact on chronic hepatitis C virus infection. Saudi J Gastroenterol (2009) 1.03
Improved detection of hepatitis B virus surface antigen by a new rapid automated assay. J Clin Microbiol (1999) 0.99
Frequent occult hepatitis B virus infection in patients infected with human immunodeficiency virus type 1. Eur J Clin Microbiol Infect Dis (2003) 0.99
Markers for hepatitis A, B and C in methadone maintained patients: an unexpectedly high co-infection with silent hepatitis B. Addiction (2008) 0.91
Prevalence of a virus similar to human hepatitis B virus in swine. Virol J (2010) 0.90
A novel stop codon mutation in HBsAg gene identified in a hepatitis B virus strain associated with cryptogenic cirrhosis. World J Gastroenterol (2003) 0.77
Anti-HBc Screening of Blood Donors in Bangladesh: Relevance to Containment of HBV Propagation. J Clin Exp Hepatol (2016) 0.75
Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol (1997) 4.08
Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy. N Engl J Med (1991) 3.14
Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus. Proc Natl Acad Sci U S A (1988) 2.98
Inhibition of human immunodeficiency virus replication by antisense oligodeoxynucleotides. Proc Natl Acad Sci U S A (1988) 2.85
Serum ferritin in patients with iron overload and with acute and chronic liver diseases. Gastroenterology (1975) 2.58
Anticardiolipin antibodies in chronic hepatitis C: implication of hepatitis C virus as the cause of the antiphospholipid syndrome. Hepatology (1996) 2.47
Inflammation and liver cancer: new molecular links . Ann N Y Acad Sci (2009) 2.29
Insulin-like growth factor-I reverts testicular atrophy in rats with advanced cirrhosis. Hepatology (2000) 2.24
Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma. J Hepatol (2000) 2.22
Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates. Proc Natl Acad Sci U S A (1988) 2.09
New therapies for hepatocellular carcinoma. Oncogene (2006) 2.05
Partial splenic embolization for the treatment of hypersplenism in cirrhosis. Hepatology (1993) 1.95
[Prevalence of antibodies against hepatitis C virus in a sample of homosexual males]. Med Clin (Barc) (1993) 1.94
Pathological and virological findings in patients with persistent hypertransaminasaemia of unknown aetiology. Gut (2000) 1.82
Transduction of hepatocellular carcinoma (HCC) using recombinant adeno-associated virus (rAAV): in vitro and in vivo effects of genotoxic agents. J Hepatol (2000) 1.73
Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C. Hepatology (1998) 1.67
[Pacemaker implantation in a patient with persistent left superior vena cava and atresia of the right superior vena cava]. Rev Port Cardiol (1994) 1.66
Serum ferritin assay and iron status in chronic renal failure and haemodialysis. Br Med J (1975) 1.61
The problem of aging human remains and living individuals: a review. Forensic Sci Int (2009) 1.59
Drug resistance in patients experiencing early virological failure under a triple combination including indinavir. AIDS (2001) 1.56
Adenovirus-mediated CD40 ligand gene therapy in a rat model of orthotopic hepatocellular carcinoma. Hepatology (2001) 1.56
Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C. Hepatology (1996) 1.56
Liver transplantation in cirrhotic patients with diabetes mellitus: midterm results, survival, and adverse events. Liver Transpl (2001) 1.44
Magnesium binding to the bacterial chemotaxis protein CheY results in large conformational changes involving its functional surface. J Mol Biol (1994) 1.44
Insulin resistance is associated with liver stiffness in HIV/HCV co-infected patients. Gut (2009) 1.43
Rituximab in CD20 positive multiple myeloma. Leukemia (2007) 1.40
Incidence and risk factors for tuberculosis in HIV-positive subjects by HAART status. Int J Tuberc Lung Dis (2008) 1.38
Liver transplantation in cirrhotic patients over 60 years of age. Rev Esp Enferm Dig (1998) 1.38
Effects of specific antibodies against Streptococcus pneumoniae on pharmacodynamic parameters of beta-lactams in a mouse sepsis model. Antimicrob Agents Chemother (2002) 1.32
Immunohistochemical detection of chloride/bicarbonate anion exchangers in human liver. Hepatology (1994) 1.32
Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes. Gut (2005) 1.28
Hepatoprotective effects of insulin-like growth factor I in rats with carbon tetrachloride-induced cirrhosis. Gastroenterology (1997) 1.25
Prediction of sustained remission of chronic hepatitis C after a 12-month course of alfa interferon. J Hepatol (1994) 1.25
Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma. Liver Transpl (2001) 1.25
Viral envelope protein of HTLV-III is the major target antigen for antibodies in hemophiliac patients. J Infect Dis (1986) 1.20
Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology (1989) 1.20
Leukocyte-cell adhesion: a molecular process fundamental in leukocyte physiology. Immunol Rev (1990) 1.18
Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients. HIV Clin Trials (2003) 1.18
Streptococcus pneumoniae isolates with reduced susceptibility to ciprofloxacin in Spain: clonal diversity and appearance of ciprofloxacin-resistant epidemic clones. Antimicrob Agents Chemother (2001) 1.18
Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy. J Immunol (2000) 1.17
Prevalence of and factors associated with visceral leishmaniasis in human immunodeficiency virus type 1-infected patients in southern Spain. J Clin Microbiol (1998) 1.17
Visceral leishmaniasis in HIV-1-infected individuals: a common opportunistic infection in Spain? AIDS (1992) 1.15
Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection. J Virol (2010) 1.15
Implication of human N-alpha-acetyltransferase 5 in cellular proliferation and carcinogenesis. Oncogene (2008) 1.15
Transmission of hepatitis C virus infection to tree shrews. Virology (1998) 1.14
Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain. AIDS (1998) 1.14
Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries. AIDS (1998) 1.14
The role of serology in the diagnosis and prognosis of visceral leishmaniasis in patients coinfected with human immunodeficiency virus type-1. Am J Trop Med Hyg (1998) 1.13
Diagnosis of infections with Leishmania infantum using PCR-ELISA. Parasitology (2001) 1.12
Induction of cytotoxic T lymphocytes in mice against the principal neutralizing domain of HIV-1 by immunization with an engineered T-cytotoxic-T-helper synthetic peptide construct. Cell Immunol (1992) 1.12
Hepatitis B and C viral infections in patients with hepatocellular carcinoma. Hepatology (1992) 1.10
Plasmacytoid dendritic cells reduce HIV production in elite controllers. J Virol (2012) 1.09
Predictive value of IgM antibodies to hepatitis C virus in patients with chronic hepatitis C undergoing interferon-alpha therapy. Analysis by two different methods. J Viral Hepat (1994) 1.08
Amphiregulin: a new growth factor in hepatocarcinogenesis. Cancer Lett (2007) 1.08
Osteopenia in rats with liver cirrhosis: beneficial effects of IGF-I treatment. J Hepatol (1998) 1.07
Identification of a novel adhesion molecule in human leukocytes by monoclonal antibody LB-2. FEBS Lett (1987) 1.05
Hepatic and extrahepatic HCV RNA strands in chronic hepatitis C: different patterns of response to interferon treatment. Hepatology (1993) 1.05
Liver cytoprotection by prostaglandins. Pharmacol Ther (1993) 1.05
Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12. Hepatology (2001) 1.04
Transjugular intrahepatic portal-systemic shunt in the treatment of refractory ascites: effect on clinical, renal, humoral, and hemodynamic parameters. Hepatology (1995) 1.03
High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients. Am J Trop Med Hyg (1999) 1.03
Electrophysiological evidence for the involvement of the locus coeruleus in alerting, orienting, and attending. Prog Brain Res (1991) 1.03
The expression of human intercellular adhesion molecule-2 is refractory to inflammatory cytokines. Eur J Immunol (1991) 1.02
An easy and quick method for the diagnosis of visceral leishmaniasis in HIV-1-infected individuals. AIDS (1993) 1.02
Insulin-like growth factor I improves intestinal barrier function in cirrhotic rats. Gut (2006) 1.02
Thermodynamic analysis of the chemotactic protein from Escherichia coli, CheY. Biochemistry (1993) 1.02
A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma. Cancer Gene Ther (2010) 1.02
Activity of fluconazole: postantifungal effect, effects of low concentrations and of pretreatment on the susceptibility of Candida albicans to leucocytes. J Antimicrob Chemother (1994) 1.01
Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity. Eur J Immunol (2001) 1.01
The response of the hepatocyte to ischemia. Liver Int (2007) 1.01
Polarity of immunogens: implications for vaccine design. Eur J Immunol (1990) 1.00
Treatment of colorectal and hepatocellular carcinomas by adenoviral mediated gene transfer of endostatin and angiostatin-like molecule in mice. Gut (2004) 1.00
In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives. J Antimicrob Chemother (2007) 1.00
Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C. Gastroenterology (1997) 1.00
Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis. Hepatology (1997) 0.99
Low doses of insulin-like growth factor-I improve nitrogen retention and food efficiency in rats with early cirrhosis. J Hepatol (1997) 0.99